There was no significant difference in the efficacy of PD-L2 expression in HCC patients evaluated by the single-sequence models (p > 0.05), while the AUCs of the training set and validation set of the combined model were significantly higher than that of any of the above single-sequence model (p < 0.05) (Figure 5). This evidence concerns the gene PDCD1LG2 and hepatocellular carcinoma.